UNLABELLED: Iodine-123-beta-CIT has been used as a probe of dopamine transporters in Parkinson's disease patients using SPECT. We studied the test/retest reproducibility of SPECT measures in Parkinson's disease patients and healthy controls obtained after injection of [123I])beta-CIT in part to assess the utility of this tracer for longitudinal evaluation of striatal dopamine transporters as a marker of disease progression. METHODS: Seven Parkinson's disease patients and seven healthy control subjects participated in two [123I]beta-CIT SPECT scans separated by 7-21 days. Subjects were imaged at 24 hr post injection of 360 MBq (9.7 mCi) of [123I]beta-CIT. Two outcome measures were evaluated; 1) the ratio of specific striatal (activity associated with DA transporter binding) to nondisplaceable uptake, also designated V3," and 2) the total specific striatal uptake (%SSU) expressed as a percentage of injected radiotracer dose. For both measures, test/retest variability was calculated as the absolute difference of test minus retest divided by the mean of test/retest and expressed as a percent. In addition, the reproducibility of left and right striatal asymmetry and putamen:caudate ratios were determined. RESULTS: The two outcome measures demonstrated excellent test/retest reproducibility for both the Parkinson's disease and healthy subject groups with variability of striatal V3" = 16.8 +/- 13.3% and percent striatal uptake = 6.8 +/- 3.4% for Parkinson's disease patients and V3" = 12.8 +/- 8.9% and %SSU = 7.0 +/- 3.9% for control subjects. There were no statistically significant differences in test/retest variability between control subjects and Parkinson's disease patients for either outcome measure. The reproducibility of left/right asymmetry indices and putamen-to-caudate ratios showed no patient versus control subject differences. The asymmetry index had greater test/retest variability than the other outcome measures. CONCLUSION: These data suggest that SPECT imaging performed at 24 hr postinjection of [123I]beta-CIT permits calculation of reliable and reproducible measures of dopamine transporters in both Parkinson's disease patients and control subjects and supports the feasibility of using [123I]beta-CIT in the evaluation of disease progression in Parkinson's disease.
UNLABELLED: Iodine-123-beta-CIT has been used as a probe of dopamine transporters in Parkinson's diseasepatients using SPECT. We studied the test/retest reproducibility of SPECT measures in Parkinson's diseasepatients and healthy controls obtained after injection of [123I])beta-CIT in part to assess the utility of this tracer for longitudinal evaluation of striatal dopamine transporters as a marker of disease progression. METHODS: Seven Parkinson's diseasepatients and seven healthy control subjects participated in two [123I]beta-CIT SPECT scans separated by 7-21 days. Subjects were imaged at 24 hr post injection of 360 MBq (9.7 mCi) of [123I]beta-CIT. Two outcome measures were evaluated; 1) the ratio of specific striatal (activity associated with DA transporter binding) to nondisplaceable uptake, also designated V3," and 2) the total specific striatal uptake (%SSU) expressed as a percentage of injected radiotracer dose. For both measures, test/retest variability was calculated as the absolute difference of test minus retest divided by the mean of test/retest and expressed as a percent. In addition, the reproducibility of left and right striatal asymmetry and putamen:caudate ratios were determined. RESULTS: The two outcome measures demonstrated excellent test/retest reproducibility for both the Parkinson's disease and healthy subject groups with variability of striatal V3" = 16.8 +/- 13.3% and percent striatal uptake = 6.8 +/- 3.4% for Parkinson's diseasepatients and V3" = 12.8 +/- 8.9% and %SSU = 7.0 +/- 3.9% for control subjects. There were no statistically significant differences in test/retest variability between control subjects and Parkinson's diseasepatients for either outcome measure. The reproducibility of left/right asymmetry indices and putamen-to-caudate ratios showed no patient versus control subject differences. The asymmetry index had greater test/retest variability than the other outcome measures. CONCLUSION: These data suggest that SPECT imaging performed at 24 hr postinjection of [123I]beta-CIT permits calculation of reliable and reproducible measures of dopamine transporters in both Parkinson's diseasepatients and control subjects and supports the feasibility of using [123I]beta-CIT in the evaluation of disease progression in Parkinson's disease.
Authors: A Winogrodzka; P Bergmans; J Booij; E A van Royen; J C Stoof; E C Wolters Journal: J Neurol Neurosurg Psychiatry Date: 2003-03 Impact factor: 10.154
Authors: Kelly P Cosgrove; Karen Tellez-Jacques; Brian Pittman; Ismene Petrakis; Ronald M Baldwin; Gilles Tamagnan; John Seibyl; Thomas Kosten; Julie K Staley Journal: Psychiatry Res Date: 2010-11-03 Impact factor: 3.222
Authors: Bernard Ravina; Kenneth Marek; Shirley Eberly; David Oakes; Roger Kurlan; Alberto Ascherio; Flint Beal; James Beck; Emily Flagg; Wendy R Galpern; Jennifer Harman; Anthony E Lang; Michael Schwarzschild; Caroline Tanner; Ira Shoulson Journal: Mov Disord Date: 2012-09-13 Impact factor: 10.338
Authors: Morten Ziebell; Gerda Thomsen; Gitte M Knudsen; Robin de Nijs; Claus Svarer; Aase Wagner; Lars H Pinborg Journal: Eur J Nucl Med Mol Imaging Date: 2006-07-29 Impact factor: 9.236
Authors: Hye Joo Son; Jungsu S Oh; Minyoung Oh; Sang Ju Lee; Seung Jun Oh; Sun Ju Chung; Jae Seung Kim Journal: Ann Nucl Med Date: 2021-01-02 Impact factor: 2.668